Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Arcutis Biotherapeutics Inc (ARQT)

270 + Investors. Track Smart Money conviction in ARQT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +6
Streak
1Q ▲
Buyers last Q
50%

Smart Money Signals — ARQT

Based on 273 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added ARQT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (98% of max)

98% of all-time peak
273 hedge funds hold ARQT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +22% more funds vs a year ago

fund count last 6Q
+49 new funds entered over the past year (+22% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 50% buying

141 buying142 selling
Last quarter: 141 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new ARQT position: 35 → 76 → 40 → 46. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 29% medium ■ 26% new
124 out of 273 hedge funds have held ARQT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

33 → 35 → 76 → 40 → 46 new funds/Q
New funds entering each quarter: 35 → 76 → 40 → 46. ARQT is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 51% veterans vs 28% newcomers

■ 51% veterans ■ 20% 1-2yr ■ 28% new
Entry-cohort mix of 280 holders: 144 (51%) are 2+ year veterans, 57 entered 1–2 years ago, and 79 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 44% AUM from top-100 funds

44% from top-100 AUM funds
52 of 272 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in ARQT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ARQT

In 2026 Q2, 141 hedge funds were net buyers of ARQT (46 opened a new position, 95 added to an existing one), while 142 reduced or exited (102 trimmed, 40 sold completely) — a 50% buyer ratio, indicating a slight buying edge. 44% of total institutional value in ARQT is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +6 funds (more new holders than closures). Total institutional holders: 273.

Hedge Fund Ownership: ARQT

How many hedge funds hold ARQT — quarterly history vs. share price
Quarterly hedge fund ownership of ARQT vs. share price

Market Analysis: ARQT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ARQT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Arcutis Biotherapeutics Inc (ARQT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ARQT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 85d ago
ARQT
-1.0%
XLV
+6.9%

ARQT outperformed XLV by -7.9% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 40d ago
ARQT
-0.9%
XLV
+1.4%

Since the filing became public, ARQT outperformed XLV by -2.3% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 4 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
4.3
/ 10
conviction
Hedge Fund Positioning: ARQT
270 + Investors

Track Smart Money conviction in ARQT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 270 267 1.12%
13F Shares 132M 133M -1.22%
Total Value $3.41B $3.09B 10.16%
New Positions 46 40 +6
Increased Positions 93 103 -10
Closed Positions 42 52 -10
Reduced Positions 99 85 +14
Total Calls 5 4 25.0%
Total Puts 3 4 -25.0%
PUT/CALL Ratio 0.6 1.0 Bullish

Statistics: ARQT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

270 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ARQT. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ARQT holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Pivotal bioVenture Partners Investment Advisor LLC 10.78% 1,265,283 $33.2M
2 Jones Hill Capital LP 6.07% 1,089,701 $28.6M
3 Montanova Capital, LLC 5.96% 12,437,000 $326.1M
4 Frazier Life Sciences Management, L.P. 5.64% 9,874,511 $258.9M
5 Pavaki Capital Management LLC 4.13% 202,000 $5.9M
6 Rubric Capital Management LP 1.99% 8,271,577 $216.9M
7 Privium Fund Management B.V. 1.92% 399,367 $10.5M
8 Patient Square Capital LP 1.50% 370,000 $9.7M
9 Fishman Jay A Ltd/Mi 1.24% 595,005 $15.6M
10 Tejara Capital Ltd 1.22% 113,084 $3.0M
11 Orbimed Advisors LLC 0.99% 2,042,000 $53.5M
12 MYDA Advisors LLC 0.94% 240,000 $6.3M
13 1492 Capital Management LLC 0.90% 116,211 $3.0M
14 Oberweis Asset Management Inc/ 0.74% 1,372,941 $36.0M
15 Lion Point Capital, LP 0.66% 5,250 $138K
16 PFM Health Sciences, LP 0.54% 242,069 $6.3M
17 Essex Investment Management Co LLC 0.47% 137,500 $3.6M
18 Stempoint Capital LP 0.45% 98,945 $2.6M
19 Perpetual Ltd 0.42% 1,109,657 $29.1M
20 Polar Capital Holdings Plc 0.41% 6,606,945 $173.2M
21 Gilder Gagnon Howe & Co LLC 0.36% 1,313,211 $34.4M
22 Virtus Investment Advisers, LLC 0.29% 47,698 $1.3M
23 PSP Research LLC 0.27% 19,700 $517K
24 Yorktown Management & Research Co Inc 0.26% 16,000 $420K
25 MFA Wealth Services 0.25% 16,196 $425K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Arcutis Biotherapeutics Inc (ARQT)

What does the Smart Money Trend signal show for ARQT?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added ARQT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ARQT?

Slight buying edge — 50% buying: Last quarter: 141 funds bought or added vs 142 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ARQT holders?

Elite ownership — 44% AUM from top-100 funds: 52 of 272 holders are among the 100 largest funds by AUM, controlling 44% of total institutional value in ARQT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ARQT?

45% of holders stayed for 2+ years: 124 out of 273 hedge funds have held ARQT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Arcutis Biotherapeutics Inc (ARQT) following the 2026 Q2 hedge fund 13F filings?

As of today, ARQT has moved -0.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to +1.4% for the XLV sector ETF — an outperformance of -2.3%. Since the quarter end (June 30, 2026), ARQT has gained -1.0% vs +6.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →